These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 30243500)

  • 1. Gene expression profiling toward the next generation safety control of influenza vaccines and adjuvants in Japan.
    Momose H; Sasaki E; Kuramitsu M; Hamaguchi I; Mizukami T
    Vaccine; 2018 Oct; 36(43):6449-6455. PubMed ID: 30243500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice.
    Wu J; Wang F; Fang F; Zhang W; Chang H; Zheng L; Chen Z
    Arch Virol; 2011 Mar; 156(3):387-95. PubMed ID: 21110049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel vaccinological evaluation of intranasal vaccine and adjuvant safety for preclinical tests.
    Sasaki E; Kuramitsu M; Momose H; Kobiyama K; Aoshi T; Yamada H; Ishii KJ; Mizukami T; Hamaguchi I
    Vaccine; 2017 Feb; 35(5):821-830. PubMed ID: 28063707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial.
    Wu J; Liu SZ; Dong SS; Dong XP; Zhang WL; Lu M; Li CG; Zhou JC; Fang HH; Liu Y; Liu LY; Qiu YZ; Gao Q; Zhang XM; Chen JT; Zhong X; Yin WD; Feng ZJ
    Vaccine; 2010 Aug; 28(38):6221-7. PubMed ID: 20638454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of a new quality control and vaccine safety test for influenza vaccines and adjuvants using gene expression profiling.
    Momose H; Mizukami T; Kuramitsu M; Takizawa K; Masumi A; Araki K; Furuhata K; Yamaguchi K; Hamaguchi I
    PLoS One; 2015; 10(4):e0124392. PubMed ID: 25909814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of DNA microarray technology to influenza A/Vietnam/1194/2004 (H5N1) vaccine safety evaluation.
    Mizukami T; Imai J; Hamaguchi I; Kawamura M; Momose H; Naito S; Maeyama J; Masumi A; Kuramitsu M; Takizawa K; Nomura N; Watanabe S; Yamaguchi K
    Vaccine; 2008 Apr; 26(18):2270-83. PubMed ID: 18374459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunologic evaluation of 10 different adjuvants for use in vaccines for chickens against highly pathogenic avian influenza virus.
    Lone NA; Spackman E; Kapczynski D
    Vaccine; 2017 Jun; 35(26):3401-3408. PubMed ID: 28511853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Wisdom to Defy an Old Enemy: Summary from a scientific symposium at the 4th Influenza Vaccines for the World (IVW) 2012 Congress, 11 October, Valencia, Spain.
    Poland GA; Fleming DM; Treanor JJ; Maraskovsky E; Luke TC; Ball EM; Poland CM
    Vaccine; 2013 Apr; 31 Suppl 1():A1-20. PubMed ID: 23587330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
    Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
    Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.
    Harada Y; Ninomiya-Mori A; Takahashi Y; Shirakura M; Kishida N; Kageyama T; Tada Y; Tashiro M; Odagiri T
    Vaccine; 2011 Oct; 29(46):8330-7. PubMed ID: 21911027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.
    Nolan TM; Richmond PC; Skeljo MV; Pearce G; Hartel G; Formica NT; Höschler K; Bennet J; Ryan D; Papanaoum K; Basser RL; Zambon MC
    Vaccine; 2008 Aug; 26(33):4160-7. PubMed ID: 18599164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal vaccination with a plant-derived H5 HA vaccine protects mice and ferrets against highly pathogenic avian influenza virus challenge.
    Major D; Chichester JA; Pathirana RD; Guilfoyle K; Shoji Y; Guzman CA; Yusibov V; Cox RJ
    Hum Vaccin Immunother; 2015; 11(5):1235-43. PubMed ID: 25714901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of protection against H5N1 influenza virus in mouse offspring provided by maternal vaccination with HA DNA and inactivated vaccine.
    Zhang F; Fang F; Chang H; Peng B; Wu J; Chen J; Wang H; Chen Z
    Arch Virol; 2013 Jun; 158(6):1253-65. PubMed ID: 23385327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.
    Lin J; Zhang J; Dong X; Fang H; Chen J; Su N; Gao Q; Zhang Z; Liu Y; Wang Z; Yang M; Sun R; Li C; Lin S; Ji M; Liu Y; Wang X; Wood J; Feng Z; Wang Y; Yin W
    Lancet; 2006 Sep; 368(9540):991-7. PubMed ID: 16980114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Madin-Darby canine kidney cell culture derived influenza A/H5N1 vaccine: a phase I trial in Taiwan.
    Pan SC; Kung HC; Kao TM; Wu H; Dong SX; Hu MH; Chou AH; Chong P; Hsieh SM; Chang SC
    J Microbiol Immunol Infect; 2013 Dec; 46(6):448-55. PubMed ID: 23022464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of marker gene expression as a potential predictive marker of leukopenic toxicity for inactivated influenza vaccines.
    Sasaki E; Momose H; Hiradate Y; Furuhata K; Takai M; Kamachi K; Asanuma H; Ishii KJ; Mizukami T; Hamaguchi I
    Biologicals; 2017 Nov; 50():100-108. PubMed ID: 28838806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
    Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.
    Nolan T; Richmond PC; Formica NT; Höschler K; Skeljo MV; Stoney T; McVernon J; Hartel G; Sawlwin DC; Bennet J; Ryan D; Basser RL; Zambon MC
    Vaccine; 2008 Nov; 26(50):6383-91. PubMed ID: 18801398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination against highly pathogenic avian influenza H5N1 virus in zoos using an adjuvanted inactivated H5N2 vaccine.
    Philippa J; Baas C; Beyer W; Bestebroer T; Fouchier R; Smith D; Schaftenaar W; Osterhaus A
    Vaccine; 2007 May; 25(19):3800-8. PubMed ID: 17403559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.